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Because of the live viral backbone of live attenuated influenza vaccine (LAIV), questions have arisen regarding infection control precautions
and restrictions surrounding its use in healthcare personnel (HCP). This document provides guidance from the Society for Healthcare
Epidemiology of America regarding use of LAIV in HCP and the infection control precautions that are recommended with its use in this
population.
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Vaccination of healthcare personnel (HCP) against influenza
is a key component of efforts to protect patients and other
HCP from healthcare-associated influenza transmission. HCP
influenza vaccination rates are slowly increasing, reaching
63.5% for the 2010–2011 influenza season,1 but they remain
well below the Healthy People 2020 Goal of 90%. Fortunately,
an increasing array of influenza vaccines are or will soon be
available to optimize recipient immune response to the vac-
cine as well as allow for different modes of vaccine delivery.
These options include various types of inactivated influenza
vaccines, such as the standard seasonal trivalent inactivated
vaccine (TIV), the high-dose TIV that produces an improved
immune response in older adults,2 and the intradermal TIV,
which uses a smaller needle and less viral antigen than the
standard intramuscular TIV.3 A new inactivated quadrivalent
vaccine is being developed that adds a second influenza B
strain in order to reduce the potential for vaccine mismatch
when compared with circulating wild-type strains.4 Finally, a
non-egg-based influenza vaccine grown in a cell line will likely
be available in the United States in a few years.5
The other major type of licensed influenza vaccine is the
live attenuated influenza vaccine (LAIV). Currently utilized
LAIVs are trivalent, but a quadrivalent LAIV vaccine (that
targets 2 strains of influenza A and 2 strains of influenza B)
was recently approved by the US Food and Drug Administra-
tion, although it is not expected to be commercially available
until the 2013–2014 influenza season. LAIV is an attenuated
live viral vaccine with a temperature-sensitive adaptation that
precludes replication of the virus at human core body tem-
peratures. Administered intranasally, the vaccine replicates in
the lower-temperature area of the nasal mucosa, allowing for
the development of mucosal as well as systemic immunity.
LAIV, which is licensed for healthy, nonpregnant persons aged
2–49 years, provides adults with another option for influenza
vaccination, particularly for those with an aversion to needles.
However, in a study of persons aged 18–49 years, although
LAIV was efficacious in preventing laboratory-confirmed in-
fluenza, it was not as efficacious as TIV, a finding that differs
from analysis of data obtained in children.6,7
On the basis of currently available data, TIV appears to be
the preferred vaccine for adults, with LAIV as an acceptable
alternative. Because of its live viral backbone, questions have
arisen regarding infection control precautions and restrictions
surrounding the use of LAIV in HCP. This document provides
guidance regarding the use of LAIV in HCP and the infection
control precautions that are recommended with its use in this
population.
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laiv and viral shedding
Shedding of attenuated vaccine virus is common in the first
few days following vaccination with LAIV;8,9 however, the
quantity of attenuated virus shed in adults is 100–10,000-fold
lower than the median human infectious dose required for
LAIV vaccination in adults.8 Reversion of LAIV virus to wild-
type virus has never been demonstrated despite extensive
testing.10 Importantly, secondary transmission from a person
who recently received the LAIV that resulted in clinically
important illness has never been reported in the medical lit-
erature,11 and to date there has been only 1 documented
episode of LAIV virus transmission, which occurred in a day
care attendee as part of a placebo-controlled LAIV trial.12 The
virus obtained from this subject retained LAIV attenuation,
and virus could not be recovered in additional specimens
collected from the subject. No additional cases of LAIV trans-
mission have been reported to the manufacturer of the only
licensed LAIV (C. Rizzo, MedImmune, personal communi-
cation, April 13, 2012).
use of laiv in hcp
On the basis of a theoretical concern for transmission and
despite the absence of evidence of an increased risk of sec-
ondary transmission of infection by LAIV recipients, the Cen-
ters for Disease Control and Prevention’s Advisory Com-
mittee on Immunization Practices and Healthcare Infection
Control Practices Advisory Committee have recommended
that LAIV not be administered to HCP who interact with
patients who at the time of contact require a protective en-
vironment (defined as a “specialized patient-care area with a
positive airflow relative to the corridor, high-efficiency par-
ticulate air filtration, and frequent air changes,” as found in
myelosuppression or stem cell transplantation units).13,14 This
recommendation was made as a result of an abundance of
caution and a desire to err on the side of patient safety.
Updated guidelines from 2010 even note that “some health-
care facilities might choose to not restrict use of LAIV in
close contacts of severely immunocompromised persons,
based on the lack of evidence for transmission in health-care
settings since licensure in 2004.”14
Studies have noted the safety of administering LAIV to
some populations of immunocompromised patients of con-
cern, including HIV-positive children15 and adults,16 older
adults with chronic obstructive pulmonary disease,17 children
with cancer,18 and adults aged 65 years and older who have
chronic medical conditions,19 although none of these studies
included subjects considered to be markedly immunocom-
promised. During the influenza A/California/7/2009 (H1N1)
pandemic, the first wave of available vaccine consisted of
LAIV and many of the initial doses of LAIV were earmarked
for HCP. Some HCP expressed concern regarding the use of
a “live” vaccine in persons that might have close contact with
immunosuppressed patients, highlighting continued confu-
sion and uncertainty regarding the use of LAIV among HCP.20
Admittedly, because most healthcare facilities have avoided
the use of LAIV in HCP, there continues to be limited ex-
perience with and data on the use of LAIV in healthcare
settings.
society for healthcare epidemiology
of america (shea) guidance on the
use of laiv in hcp
SHEA endorses the use of LAIV as an alternative to the in-
activated influenza vaccine, particularly for those HCP who
avoid an annual influenza vaccination because of fear of nee-
dle injections. SHEA also agrees with the restriction of LAIV
from those HCP who, in the week following vaccination, have
frequent contact with patients who reside in a protective en-
vironment (eg, HCP in a bone marrow transplantation unit),
but it notes that this recommendation is made as a result of
an abundance of caution. Those HCP who have frequent
contact with patients in protective environments but who will
not care for such patients in the week following vaccination
may still receive LAIV. HCP who have the potential for in-
frequent contact with patients in protective environments (ie,
when the majority of patients contacted do not reside in a
protective environment, such as a radiology technologist per-
forming a chest radiograph or an emergency department phy-
sician during the initial patient evaluation) should not be
excluded from vaccination with LAIV. Finally, HCP who pro-
vide care to other immunosuppressed populations (eg, neo-
natal and burn unit patients and oncologic patients under-
going chemotherapy but not requiring a formal protective
environment) may still receive LAIV.
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